Literature DB >> 11168640

The identification of plant lectins with mucosal adjuvant activity.

E C Lavelle1, G Grant, A Pusztai, U Pfüller, D T O'Hagan.   

Abstract

To date, the most potent mucosal vaccine adjuvants to be identified have been bacterial toxins. The present data demonstrate that the type 2 ribosome-inactivating protein (type 2 RIP), mistletoe lectin I (ML-I) is a strong mucosal adjuvant of plant origin. A number of plant lectins were investigated as intranasal (i.n.) coadjuvants for a bystander protein, ovalbumin (OVA). As a positive control, a potent mucosal adjuvant, cholera toxin (CT), was used. Co-administration of ML-I or CT with OVA stimulated high titres of OVA-specific serum immunoglobulin G (IgG) in addition to OVA-specific IgA in mucosal secretions. CT and ML-I were also strongly immunogenic, inducing high titres of specific serum IgG and specific IgA at mucosal sites. None of the other plant lectins investigated significantly boosted the response to co-administered OVA. Immunization with phytohaemagglutinin (PHA) plus OVA elicited a lectin-specific response but did not stimulate an enhanced response to OVA compared with the antigen alone. Intranasal delivery of tomato lectin (LEA) elicited a strong lectin-specific systemic and mucosal antibody response but only weakly potentiated the response to co-delivered OVA. In contrast, administration of wheatgerm agglutinin (WGA) or Ulex europaeus lectin 1 (UEA-I) with OVA stimulated a serum IgG response to OVA while the lectin-specific responses (particularly for WGA) were relatively low. Thus, there was not a direct correlation between immunogenicity and adjuvanticity although the strongest adjuvants (CT, ML-I) were also highly immunogenic.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168640      PMCID: PMC1783150          DOI: 10.1046/j.1365-2567.2001.01157.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  37 in total

1.  Mucosal immunogenicity of plant lectins in mice.

Authors:  E C Lavelle; G Grant; A Pusztai; U Pfüller; D T O'Hagan
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4.

Authors:  M Marinaro; H F Staats; T Hiroi; R J Jackson; M Coste; P N Boyaka; N Okahashi; M Yamamoto; H Kiyono; H Bluethmann; K Fujihashi; J R McGhee
Journal:  J Immunol       Date:  1995-11-15       Impact factor: 5.422

Review 3.  The mechanism of cholera toxin adjuvanticity.

Authors:  N Lycke
Journal:  Res Immunol       Date:  1997 Oct-Dec

4.  Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins.

Authors:  P J Giannasca; J A Boden; T P Monath
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

5.  Characterization of recombinant and plant-derived mistletoe lectin and their B-chains.

Authors:  J Eck; M Langer; B Möckel; K Witthohn; H Zinke; H Lentzen
Journal:  Eur J Biochem       Date:  1999-10

6.  Lectin-induced modulation of the antibody response to type III pneumococcal polysaccharide.

Authors:  C E Taylor; P W Stashak; G Caldes; B Prescott; B J Fowlkes; P J Baker
Journal:  Cell Immunol       Date:  1984-01       Impact factor: 4.868

7.  Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens.

Authors:  J D Clements; N M Hartzog; F L Lyon
Journal:  Vaccine       Date:  1988-06       Impact factor: 3.641

8.  Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants.

Authors:  G Douce; C Turcotte; I Cropley; M Roberts; M Pizza; M Domenghini; R Rappuoli; G Dougan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

9.  Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis.

Authors:  M Pizza; M Domenighini; W Hol; V Giannelli; M R Fontana; M M Giuliani; C Magagnoli; S Peppoloni; R Manetti; R Rappuoli
Journal:  Mol Microbiol       Date:  1994-10       Impact factor: 3.501

10.  Oral immunization with the B subunit of the heat-labile enterotoxin of Escherichia coli induces early Th1 and late Th2 cytokine expression in Peyer's patches.

Authors:  I Nakagawa; I Takahashi; H Kiyono; J R McGhee; S Hamada
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

View more
  16 in total

Review 1.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 2.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

3.  Mucosal adjuvant properties of the Shigella invasin complex.

Authors:  Robert W Kaminski; K Ross Turbyfill; Edwin V Oaks
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

4.  Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α.

Authors:  Inna S Afonina; Graham A Tynan; Susan E Logue; Sean P Cullen; Michael Bots; Alexander U Lüthi; Emer P Reeves; Noel G McElvaney; Jan P Medema; Ed C Lavelle; Seamus J Martin
Journal:  Mol Cell       Date:  2011-10-21       Impact factor: 17.970

5.  Expression of functional hexahistidine-tagged ricin B in tobacco.

Authors:  Deborah G Reed; Luis H Nopo-Olazabal; Vanessa Funk; Bonnie J Woffenden; Michael J Reidy; Maureen C Dolan; Carole L Cramer; Fabricio Medina-Bolivar
Journal:  Plant Cell Rep       Date:  2004-12-15       Impact factor: 4.570

6.  Mistletoe lectins enhance immune responses to intranasally co-administered herpes simplex virus glycoprotein D2.

Authors:  E C Lavelle; G Grant; A Pusztai; U Pfüller; O Leavy; E McNeela; K H G Mills; D T O'Hagan
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

Review 7.  Plant-derived immuno-adjuvants in vaccines formulation: a promising avenue for improving vaccines efficacy against SARS-CoV-2 virus.

Authors:  Arbind Kumar; Aashish Sharma; Narendra Vijay Tirpude; Yogendra Padwad; Vipin Hallan; Sanjay Kumar
Journal:  Pharmacol Rep       Date:  2022-09-20       Impact factor: 3.919

8.  Phytic acid modulates in vitro IL-8 and IL-6 release from colonic epithelial cells stimulated with LPS and IL-1beta.

Authors:  Ludmiła Weglarz; Joanna Wawszczyk; Arkadiusz Orchel; Marzena Jaworska-Kik; Zofia Dzierzewicz
Journal:  Dig Dis Sci       Date:  2006-12-12       Impact factor: 3.487

Review 9.  Safety of higher dosages of Viscum album L. in animals and humans--systematic review of immune changes and safety parameters.

Authors:  Gunver S Kienle; Renate Grugel; Helmut Kiene
Journal:  BMC Complement Altern Med       Date:  2011-08-28       Impact factor: 3.659

10.  Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant.

Authors:  Ignazio Castagliuolo; Marina Sardina; Paola Brun; Chiara DeRos; Cristina Mastrotto; Laura Lovato; Giorgio Palù
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.